Therapy Areas: Oncology
Telix to present 20 abstracts on cancer theranostics at EANM Congress
14 October 2026 - Radiopharmaceutical company Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced on Wednesday that it will present 20 company-related abstracts at the 39th European Associ...
CelLBxHealth secures USD65,000 pharmaceutical research contract
14 October 2026 - CTC intelligence company CelLBxHealth plc (AIM: CLBX) reported on Wednesday that it has signed a new Statement of Work (SOW) worth approximately USD65,000 under an existing Master Se...
Racura Oncology receives approval for RC220 trial to proceed to higher dose
13 October 2026 - Racura Oncology Limited (ASX:RAC), a late clinical-stage biopharmaceutical company, announced on Monday that the Safety Review Committee (SRC) for the Phase 1 HARNESS-1 trial has app...
Foresee gains NMPA approval for CAMCEVI 42 mg in China
12 October 2026 - Taiwan and US-based biopharmaceutical company Foresee Pharmaceuticals Co., Ltd. (TPEX: 6576) said on Monday that its partner Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci), ...
ABL Texcell Diagnostics acquires IntegraGen assets to expand into precision oncology
12 October 2026 - ABL Texcell Diagnostics (Euronext Paris:ABLD), a provider of molecular biology tests, said on Monday that it has acquired IntegraGen's assets and business operations following a...
Perceptive Discovery partners with Nucleus RadioPharma Inc to accelerate radiopharmaceutical development
12 October 2026 - Perceptive Discovery, a preclinical and translational research organisation supporting oncology, CNS, and radiopharmaceutical development, announced on Friday that it has formed a st...